Riliprubart

6 trials 3 recruiting Orphan designation

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

3 Completed trials

2 Sponsors

15 Countries

Phase III

Phase II

Phase I (Other)

Phase III: 3 Phase II: 2 Phase I (Other): 1

Indications tested

Autoimmune haemolytic anaemia 1 Transplant rejection 1 Chronic inflammatory demyelinating polyradiculoneuropathy 1

Sponsors using this IMP

Sanofi-Aventis Recherche & Developpement 5 Bioverativ USA Inc. 1

All trials

6 total

Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting

2024-517032-22-00 Phase III 14 countries Sanofi-Aventis Recherche & Developpement
BIVV020 (SAR445088) in prevention and treatment of antibody-mediated rejection (AMR) Recruiting

2023-509936-25-00 Phase II 5 countries Sanofi-Aventis Recherche & Developpement
A study to test the efficacy and safety of riliprubart against the usual treatment of intravenous immunoglobulin (IVIg) in people with chron… Recruiting

2023-508338-33-00 Phase III 13 countries Sanofi-Aventis Recherche & Developpement
A study to test the effects and safety of riliprubart in people with chronic inflammatory demyelinating polyneuropathy (CIDP) for which the … Ended

2023-506503-26-00 Phase III 13 countries Sanofi-Aventis Recherche & Developpement
Proof-of-concept study for SAR445088 in chronic inflammatory demyelinating polyneuropathy (CIDP) Ended

2024-512345-16-00 Phase II 6 countries Sanofi-Aventis Recherche & Developpement
An open-label, long-term, safety and tolerability study of SAR445088 in participants with cold agglutinin disease previously treated with SA… Ended

2023-510210-68-00 Phase I (Other) 3 countries Bioverativ USA Inc.

Showing 1–6 of 6 trials

← All drugs A–Z